Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol
Rhea-AI Summary
Alps Group (NASDAQ:ALPS) published a peer-reviewed case series (Feb 2026) reporting safety and tolerability data from nine patients who received autologous NK cell infusions produced with its in-house culture protocol.
The study (NMRR ID 25-00333-MUM) and Malaysian patent application PI2025002484 describe an antibody-free, cost-efficient method for large-scale NK cell production and aim to support future clinical trials.
Positive
- Peer-reviewed publication reporting clinical case series safety data
- Study registered with NMRR ID 25-00333-MUM
- Patent-pending antibody-free culture method (PI2025002484)
- Preliminary safety/tolerability observed in nine infused patients
- Company reports supporting GLP preclinical data for next studies
Negative
- Very small clinical sample: only nine nonconsecutive patients
- Efficacy not demonstrated in clinical patients; only in vitro cytotoxicity
- Cytotoxicity assessed in pilot cultures, not as batch-release testing
- Findings are preliminary and intended to inform future investigations
Key Figures
Market Reality Check
Peers on Argus
No peer stocks were flagged in the momentum scanner and no same-day peer headlines were recorded, suggesting this move is company-specific rather than part of a sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 30 | Pipeline expansion | Positive | +4.3% | Peer-reviewed case series supported potential expansion of exosome therapy pipeline. |
| Jan 08 | Executive appointment | Positive | +2.0% | Appointment of experienced CFO to lead financial strategy and controls. |
| Oct 31 | Business combination | Positive | +15800.6% | Closing of Globalink business combination and start of Nasdaq trading. |
Recent company announcements, including pipeline and corporate milestones, were followed by positive price reactions.
Over the past several months, Alps Group moved from a SPAC business combination to building visibility around its biotech platform. The closing of the Globalink deal on Oct 31, 2025 and Nasdaq listing produced a sharp positive move. Subsequent news on potential exosome pipeline expansion on Jan 30, 2026 and the CFO appointment on Jan 8, 2026 also saw positive reactions. Today’s autologous NK cell safety and tolerability data fits a pattern of early-stage clinical validation updates following the combination.
Market Pulse Summary
This announcement adds peer-reviewed safety and tolerability data from a nine-patient autologous NK cell case series, reinforcing Alps Group’s focus on next-generation cell therapies. The publication complements earlier disclosures that its pipeline remains preclinical and that recent losses reached $66.2 million. Investors may watch for larger, controlled studies, regulatory interactions, and how future financings are managed as the company scales its in-house culture protocol toward broader clinical development.
Key Terms
autologous medical
natural killer (nk) cells medical
good clinical practice regulatory
cytotoxicity medical
immunotherapy medical
AI-generated analysis. Not financial advice.
KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a peer-reviewed case study in the February 2026 edition of SAGE Open Medical Case Reports.
The publication reports findings from nine patients who received autologous Natural Killer (NK) cell infusions produced using the Company’s in-house developed culture protocol. Natural Killer (NK) cells are a type of immune cell involved in the body’s natural defense against abnormal cells.
The patients were monitored pre- and post-infusion for hematological parameters, liver function, hypersensitivity reactions, inflammatory markers as well as tumor markers to assess for potential NK cell-induced or any dose-dependent toxic/adverse reactions. The study provided evidence of clinical tolerability of the autologous NK cells cultured using the Company’s proprietary protocol.
The clinical case series study was registered with the National Medical Research Register, Ministry of Health Malaysia, with NMRR ID 25-00333-MUM. Data collection and analysis were conducted in accordance with the ethical principles of the Declaration of Helsinki and Malaysian Good Clinical Practice guidelines. The study involved nine nonconsecutive patients who received NK cell infusions at ALPS Medical Centre between 2023 and 2024.
Dr. Tham Seng Kong, Chief Executive Officer of Alps Group, stated, “Based on these preliminary observations, our in-house developed NK cells appear to be safe for use. The NK cells also exhibited cytotoxicity toward in vitro cultured and co-incubated cancer cell models; however, this was assessed using pilot cultures rather than as part of batch-release testing.”
A notable aspect of this case series is the Company’s patent-pending, antibody-free culture method (Malaysian patent application no. PI2025002484) which enables cost-effective, large-scale production of highly pure natural killer (NK) cells using basic culture media and autologous plasma. This approach improves the safety profile of NK cells and lowers manufacturing barriers, potentially making advanced immunotherapy more accessible and efficient.
Preliminary case series data supports the safety of this method, positioning Alps Group at the forefront of scalable, next-generation autologous immune cell therapy solutions. Together with preclinical GLP study data, the findings from this study are intended to support the design of future clinical investigations in a broader patient population.
Details of the study and its findings have been peer-reviewed and published in SAGE Open Medical Case Reports, accessible at:
https://journals.sagepub.com/doi/epub/10.1177/2050313X251376950
About Alps Group
Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. Alps Group’s mission is to create a fair healthcare ecosystem, to make advance predictive, preventive, and precision medicine accessible and affordable.
Forward-Looking Statements
Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
A further list and description of risks and uncertainties can be found in documents filed with the Securities and Exchange Commission (“SEC”) by the Company and other documents that we may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.
Investor Relations Contact
Andrew J. Barwicki
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
What did Alps Group (ALPS) publish in February 2026 about NK cell therapy?
How many patients were included in the Alps Group (ALPS) NK cell safety study?
Does the Alps Group (ALPS) study show clinical effectiveness of its NK cells?
What is special about Alps Group's (ALPS) NK cell manufacturing method?
How will the Alps Group (ALPS) case series affect future clinical trials?
